Saturday , April 4 2026
Home / Media OutReach / Enapter AG: Entry of a strategic investor – Conclusion of an investment agreement and a cooperation agreement with Johnson Matthey

Enapter AG: Entry of a strategic investor – Conclusion of an investment agreement and a cooperation agreement with Johnson Matthey



Enapter AG: Entry of a strategic investor – Conclusion of an investment agreement and a cooperation agreement with Johnson Matthey | Media OutReach














Publication of inside information pursuant to Article 17 MAR

BERLIN, GERMANY – EQS Newswire – 25 May 2022 – Enapter AG (ISIN: DE000A255G02) today successfully concluded negotiations for the entry of a strategic investor. Enapter has agreed on an investment agreement and a cooperation agreement with Johnson Matthey (ISIN: GB00BZ4BQC70), a multinational specialty chemicals and sustainable technologies company headquartered in London, United Kingdom.

Johnson Matthey will acquire approximately 1.05 million Enapter shares at a price of EUR 19.00 per share within the framework of the current capital increase, thus investing a total amount of approximately EUR 20 million. Furthermore, Enapter and Johnson Matthey have agreed on a strategic cooperation in the field of catalysts and membrane development with a minimum term until 31 March 2026. During the term of the cooperation, the cooperation partners will share joint developments and grant a license to use each other’s proprietary developments after an exclusivity period of 36 months.

The issuer is solely responsible for the content of this announcement.

About Enapter AG:

Enapter is an award-winning energy technology company producing highly efficient hydrogen generators to replace fossil fuels. Its patented and proven Anion Exchange Membrane (AEM) technology allows for the mass production of low-cost, plug-&-play electrolysers for green hydrogen at any scale. The modular systems are already used in 47 countries in sectors like energy, mobility, industry, heating and telecommunications.

#Enapter


PUBLISHED ON:

25 May 2022


Source link

About admin

Check Also

CK Life Sciences’ Sequencio Therapeutics Presents the Latest Vaccine Research Advancements at the American Association for Cancer Research Annual Meeting

HONG KONG SAR – Media OutReach Newswire – 31 March 2026 – Sequencio Therapeutics Company …

Leave a Reply

Your email address will not be published.